Dupixent (dupilumab) / Sanofi, Regeneron - LARVOL DELTA

Immune Checkpoint Inhibitor-Associated Autoimmune Bullous Diseases: Beyond Bullous Pemphigoid. (PubMed, Int J Dermatol) - No abstract available

Checkpoint inhibition • Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Oncology

Comprehensive Assessment of Symptoms, Comorbidities, and Treatment Response in Individuals with Atopic Dermatitis Treated at a Referral Centre between 2018 and 2022. (PubMed, Indian J Dermatol) - "Additionally, patients treated with dupilumab experienced a 30% decrease in clinical evaluation scores during follow-up...It is important to know data such as age of onset, symptoms, common lesion locations according to age, comorbidities, and treatment responses. This information is fundamental for selecting appropriate therapies, ensuring effective follow-up, and improving quality of life."

Journal • Atopic Dermatitis • Cardiovascular • CNS Disorders • Dermatitis • Dermatology • Immunology • Inflammation • Mental Retardation • Pruritus • Psychiatry

Dupilumab Treatment for Atopic Dermatitis Associated with Reduced Risk of Alopecia Areata: A Multicenter Cohort Study. (PubMed, J Allergy Clin Immunol Pract) - No abstract available

Journal • Allergy • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents. (PubMed, Cureus) - "This Bayesian network meta‑analysis (BNMA) provides the first unified evaluation of all biologic monoclonal antibodies approved as monotherapy for AD (dupilumab, lebrikizumab, tralokinumab) together with emerging immunotherapies, including amlitelimab, rademikibart, rezpegaldesleukin, rocatinlimab, telazorlimab, temtokibart, and zumilokibart, across key efficacy measures.  A PRISMA‑2020-compliant systematic review and PROSPERO‑registered protocol (CRD420251162704) identified phase 2-3 randomized, double‑blind, placebo‑controlled trials reporting week‑16 outcomes (week‑24 for rocatinlimab). Zumilokibart, rademikibart, and temtokibart emerge as additional candidates with encouraging activity, whereas telazorlimab showed limited clinical benefit. Collectively, these findings provide a comprehensive comparative framework to inform biologic selection and therapeutic sequencing."

Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Dupilumab for Chronic Spontaneous Urticaria with Comorbid Type 2 Inflammatory Conditions: Case Report and Systematic Review of the Literature. (PubMed, Case Rep Dermatol) - "Chronic spontaneous urticaria (CSU) is a heterogeneous, Th2-driven condition where standard therapies, including antihistamines and omalizumab, are often insufficient. The majority achieved symptom control of urticaria as well as of the coexisting Th2 diseases, with only one report of mild side effects. Dupilumab is a suitable therapeutic option in patients with CSU and coexisting Th2-mediated conditions."

Journal • Asthma • Atopic Dermatitis • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Immunology • Pulmonary Disease • Respiratory Diseases • Urticaria

AIM4:Next Step: Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (clinicaltrials.gov) - P4 | N=250 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - P1 | N=86 | Active, not recruiting | Sponsor: Apogee Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Serum Cytokine Dynamics in Dupilumab-Induced Psoriasiform Dermatitis: A Case Report. (PubMed, J Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies. (PubMed, Expert Opin Biol Ther) - "We reviewed pivotal phase 3 and 4 trials (including SINUS-52, SYNAPSE, OSTRO, WAYPOINT, and the head-to-head EVEREST trial) evaluating dupilumab, mepolizumab, benralizumab, omalizumab, and tezepelumab. Emerging data from the WAYPOINT trial suggests tezepelumab (anti-TSLP) as a potent option for broad epithelial blockade. We advocate moving beyond isolated disease control toward a stratified 'United Airway' remission target guided by fractional exhaled nitric oxide, blood eosinophils, and immunoglobulin E levels."

Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • IL5

Improvement of depressive symptoms in patients with severe atopic dermatitis treated with dupilumab: an open-label trial validated using the Beck depression inventory, Hamilton depression rating scale measures, and 18F-fluorodeoxyglucose positron emission tomography. (PubMed, Eur J Dermatol) - No abstract available

Journal • Atopic Dermatitis • CNS Disorders • Depression • Dermatitis • Dermatology • Immunology • Mood Disorders • Psychiatry

Challenges in Differentiating Chronic Inducible Urticaria from Chronic Spontaneous Urticaria. (PubMed, J Inflamm Res) - "Treatment is outlined according to current guidelines and evidence, noting that while second-generation H1-antihistamines are first-line for all CU patients, patients with CIndU often require trigger avoidance and occasionally off-label therapies (eg, omalizumab) for adequate control. In addition, this review discusses emerging treatments for CU, such as dupilumab, Bruton's tyrosine kinase (BTK) inhibitors, and barzolvolimab, which reflect the rapidly evolving therapeutic landscape. This review provides a practical guide for clinicians to differentiate and manage CSU and CIndU, by identifying key differences between CSU and CIndU based on current evidence."

Journal • Review • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Impact of Dupilumab on Small Airway Disease in Severe Asthma: A 12-Month Retrospective Real-World Study. (PubMed, Adv Respir Med) - "Improvements in R5-R20 correlated with better ACT and FeNO reductions. In this real-world cohort, dupilumab significantly improved SAD, lung function, and asthma control, while reducing exacerbations, OCS dependence, and type 2 inflammation over 12 months."

Journal • Real-world evidence • Retrospective data • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Impact of Dupilumab on the Skin Microbiome in Children Aged 6-12 years with Moderate-to-Severe Atopic Dermatitis. (PubMed, J Asthma Allergy) - "Our findings suggest that the therapeutic action of dupilumab may extend to modulating a wider range of bacteria than previously recognized. The roles of our identified candidate microbial taxa require further investigation in larger and functional studies."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics • Pruritus

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid (Sanofi Press Release) - "The approval in Japan is based on data from the pivotal LIBERTY-BP-ADEPT phase 2/3 study (clinical study identifier: NCT04206553), which evaluated Dupixent in adults with moderate-to-severe BP."

Japan approval • Bullous Pemphigoid • Immunology

Dupilumab Significantly Improves the Likelihood of Achieving Clinical Remission Components in Patients With Moderate-to-Severe Asthma and Markedly Elevated Eosinophils and FeNO: Win Ratio Analysis of QUEST (EAACI 2026) - No abstract available

Clinical • Immunology

Mechanisms of Improvement of Respiratory Symptoms and Clinical Outcomes With Dupilumab: Causal Mediation Analyses of BOREAS and NOTUS (EAACI 2026) - No abstract available

Clinical • Clinical data • Immunology

Dupilumab + AIT: CD8⁺ T Cells Uncover a Potent Immune Reset in Severe Allergic patients (EAACI 2026) - No abstract available

Clinical • Immunology

Impact of Airway Damage in Chronic Obstructive Pulmonary Disease Response to Dupilumab Treatment: Results From BOREAS and NOTUS (EAACI 2026) - No abstract available

Allergy • Immunology

Dupilumab Improves Histologic and Endoscopic Features of Pediatric Onset Eosinophilic Esophagitis (EoE): Pooled Results From the EoE KIDS And Liberty EoE TREET Studies (EAACI 2026) - No abstract available

Clinical • Immunology

Dupilumab therapy of patients with chronic rhinosinusitis with nasal polyps: long-term observational study (EAACI 2026) - No abstract available

Clinical • Observational data • Immunology

Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD (EAACI 2026) - No abstract available

Immunology

Efficacy of dupilumab vs omalizumab on symptom and quality of life burden in patients with severe chronic rhinosinusitis with nasal polyps and coexisting asthma: Results from the EVEREST study (EAACI 2026) - No abstract available

Clinical • HEOR • Allergy • Immunology

Dupilumab Modulates Humoral Immunity in IgE-Mediated Food Allergy: Adults and Children (EAACI 2026) - No abstract available

Clinical • Allergy • Food Hypersensitivity • Immunology

Clinically meaningful improvements in upper airway outcomes with dupilumab vs omalizumab by prior surgery status in severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST study) (EAACI 2026) - No abstract available

Clinical • Surgery • Immunology

Food Reintroduction Among Children with Eosinophilic Esophagitis on Dupilumab: Post Hoc Analysis of EoE KIDS Study at 100 Weeks (EAACI 2026) - No abstract available

Clinical • Retrospective data • Immunology